06.01.2015 23:50:12
|
Landec Profit Falls; FY16 Outlook Strong
(RTTNews) - Landec Corp (LNDC) on Tuesday reported net earnings of $3.2 million or $0.12 per share for the second quarter of fiscal year 2015. This compares with a profit of $3.5 million or $0.13 per share last year.
Analysts polled by Thomson Reuters estimated earnings of $0.12 per share for the quarter. Analysts' estimates typically exclude special items.
Landec noted that its results were hurt by the smaller increase in the fair market value of its investment in Windset Farms, compared with last year.
Revenues for the quarter were $132.7 million compared with $120 million in the prior year. Analysts estimated revenues of $127 million.
For the fiscal year 2016, the company expects revenues to grow by as much as 10% from the prior year, net income estimated to rise more than 50% to an upper range of $1.00 per share.
Analysts expect revenue growth of 8.7% and earnings of $0.98 per share for 2016.
Landec makes differentiated products in food and biomedical materials markets.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Lifecore Biomedicalmehr Nachrichten
17.01.25 |
NASDAQ Composite Index-Papier Lifecore Biomedical-Aktie: So viel Verlust hätte ein Investment in Lifecore Biomedical von vor einem Jahr eingebracht (finanzen.at) | |
15.01.25 |
Pluszeichen in New York: NASDAQ Composite verbucht am Nachmittag Gewinne (finanzen.at) | |
14.01.25 |
Pluszeichen in New York: NASDAQ Composite zeigt sich zum Start des Dienstagshandels fester (finanzen.at) | |
10.01.25 |
Zurückhaltung in New York: NASDAQ Composite verliert schlussendlich (finanzen.at) | |
10.01.25 |
NASDAQ Composite aktuell: NASDAQ Composite verbucht am Freitagnachmittag Verluste (finanzen.at) | |
10.01.25 |
Zurückhaltung in New York: NASDAQ Composite am Freitagmittag in der Verlustzone (finanzen.at) | |
10.01.25 |
NASDAQ Composite Index-Wert Lifecore Biomedical-Aktie: So viel Verlust hätte eine Lifecore Biomedical-Investition von vor 10 Jahren eingebracht (finanzen.at) | |
10.01.25 |
Börse New York: NASDAQ Composite zeigt sich zum Start des Freitagshandels schwächer (finanzen.at) |
Analysen zu Lifecore Biomedicalmehr Analysen
Aktien in diesem Artikel
Lifecore Biomedical | 6,20 | 0,00% |